Brief: BioCryst Pharmaceuticals Q1 EPS USD -0.17 Vs. IBES Estimate USD -0.21
06/05/2024 12:00
May 06 (Reuters) - BioCryst Pharmaceuticals Q1 operating income USD -14.5 million vs. IBES estimate USD -23 million. * Q1 net income USD -35.4 million vs. IBES estimate USD -43 million * Q1 product sales USD 88.9 million
Recent news on BioCryst Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
Brief: Biocryst Announces Approval Of Orladeyo® For Pediatric Hae Patients In Japan
BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Biocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026